QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS ...Middle East

PR Newswire - News
QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
First patient dosed in Canada in Phase 1 ANQUR study – the first-ever clinical trial to evaluate a therapy that rescues STATHMIN-2 expression in ALS patients STATHMIN-2 is a well-validated protein important for neural repair and axonal stability, the expression of which is significantly...

Hence then, the article about quralis announces first patient dosed with qrl 201 a first in class stathmin 2 precision therapy for als was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS )

Apple Storegoogle play

Last updated :

Also on site :